For research and development scientists in the pharmaceutical sector, the efficiency and yield of API synthesis are directly tied to the quality of the starting materials. 5-Amino-3-(4-phenoxyphenyl)-1H-pyrazole-4-carbonitrile, identified by CAS number 330792-70-6, plays a pivotal role as an intermediate in the synthesis of Ibrutinib, a highly effective Bruton's tyrosine kinase (BTK) inhibitor. Understanding its chemical properties and how to procure it from reliable sources can optimize your synthetic routes and accelerate drug development.

The chemical structure of 5-Amino-3-(4-phenoxyphenyl)-1H-pyrazole-4-carbonitrile, often appearing as an off-white to light yellow powder, provides the foundational pyrazole core necessary for building the complex Ibrutinib molecule. Its purity, typically specified at ≥98.0%, is critical. Impurities in such key intermediates can lead to side reactions, reduced yields, and difficulties in purification of the final API, potentially impacting regulatory approval and therapeutic efficacy. Therefore, scientists often search for 'high purity pyrazole derivative' or 'ibrutinib intermediate manufacturer' to find dependable suppliers.

When developing synthetic strategies, R&D chemists and product formulators need assurance of consistent product quality. This includes detailed analytical data such as High-Performance Liquid Chromatography (HPLC) assays, mass spectrometry, and structural verification. Establishing a relationship with a manufacturer that can provide comprehensive technical support, including Certificates of Analysis (CoA) and Methods of Analysis (MoA), is invaluable. This allows for seamless integration of the intermediate into established or novel synthetic pathways.

The commercial aspect is also a consideration, even in early-stage R&D. Knowing where to find 'CAS 330792-70-6 price' or 'pharmaceutical intermediate supplier' helps in budgeting and project planning. Companies looking to scale up their research will benefit from suppliers who can readily provide bulk quantities while maintaining the same high purity standards. By prioritizing quality intermediates from reputable manufacturers, scientists can enhance the efficiency and reliability of their Ibrutinib synthesis, driving forward the development of crucial cancer therapies.